News | October 02, 2013

New Molecular Imaging Agents Being Developed for Fluorescence-Guided Brain Cancer Surgery

Dartmouth, LI-COR and Affibody receive NIH grant for development and translation of imaging agents for fluorescence-guided surgery

nuclear imaging clinical trial study radiopharmaceuticals tracers li-cor

October 2, 2013 —The Thayer School of Engineering and Geisel School of Medicine at Dartmouth together with LI-COR Biosciences and Affibody AB announced a new partnership to establish an efficient pipeline for development and translation of molecularly targeted agents. The National Cancer Institute funds the five-year project.

The study will use a cost-effective, risk-diluted approach for rapid development and testing of molecularly-targeted imaging agents in phase 0 microdosing studies. The microdosing studies are designed to evaluate imaging of specific targets.

“Targeting an evaluation of imaging in early human surgical trials will allow us to efficiently assess potential candidates for further development,” said Brian Pogue, Ph.D., lead investigator and Dartmouth professor. “This approach will dramatically accelerate the paradigm shift to molecularly guided surgical oncology. This grant will allow us to develop and test agents produced with current Good Manufacturing Practices whose primary use will be in diagnostic guidance in surgical oncology, and used at microdoses similar to nuclear medicine tracers.”

The first agent will be an Affibody molecule targeted to the epidermal growth factor receptor (EGFR), which is overexpressed in a broad range of cancers.

Fredrik Frejd, Ph.D., chief science officer, Affibody. “Due to the high target specificity and favorable tissue distribution properties of Affibody molecules, tumors and their boundaries can be rapidly identified and characterized, which may allow for the development of image-guided surgery as a potential option for improved brain tumor treatment.”

The study will employ commercially available state-of-the-art surgical microscopes from Leica and Zeiss that are equipped for intraoperative fluorescence imaging. Surgical signal detection and binding specificity will be the primary outcomes from the phase 0 trials. First-in-human studies with recurrent high-grade brain tumor patients will be pursued at Dartmouth. Approval for the microdosing studies will be sought under the exploratory investigational new drug (IND) pathway at the FDA.

For more information: www.licor.com

Related Content

CT Offers Non-Invasive Alternative for Complex Coronary Disease Treatment Planning
News | CT Angiography (CTA) | October 16, 2018
A new study published in the European Heart Journal shows computed tomography (CT) can be a useful aid in heart team...

Images from computed tomography (CT) colonography show segmented abdominal aortic calcification measured with semiautomated CT tool on coronal image. Within region of interest over aorta selected by user, tool automatically segments and quantifies aortic calcification (shown in blue). 

Image Credit: O’Connor S D, Graffy P M, Zea R, et al. Does nonenhanced CT-based quantification of abdominal aortic calcification outperform the Framingham Risk Score in predicting cardiovascular event sin asymptomatic adults? Radiology doi: 10.1148/radiol.2018180562. Published online Oct. 2, 2018. © RSNA.

News | Computed Tomography (CT) | October 12, 2018
Computed tomography (CT)-based measures of calcification in the abdominal aorta are strong predictors of heart attacks...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
Adherence to Annual Lung Cancer Screening Needs Improvement
News | Lung Cancer | October 03, 2018
A study of adherence to annual low-dose computed tomography (LDCT) screening within the Veteran Health Administration...
Xoft Electronic Brachytherapy System Effective Long-Term for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 02, 2018
Breast cancer recurrence rates for patients treated with the Xoft Axxent Electronic Brachytherapy (eBx) System that...
CyberKnife System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
News | Stereotactic Body Radiation Therapy (SBRT) | September 27, 2018
Accuray Inc. announced that published data from two prospective, multi-center studies using differing protocols provide...